{"component": "clause", "props": {"groups": [{"snippet": "JT and Tularik may each prepare and submit to the JDC for consideration plans for development of Product line extensions and the conduct of clinical trials covering indications other than those for which Products are being developed or commercialized in the Territory. Any such line extensions or any additional clinical trials for additional indications will be subject to the approval and supervision of the JDC as part of the ongoing Development of such Product.", "size": 4, "snippet_links": [{"key": "submit-to", "type": "definition", "offset": [36, 45]}, {"key": "the-jdc", "type": "clause", "offset": [46, 53]}, {"key": "product-line-extensions", "type": "clause", "offset": [97, 120]}, {"key": "conduct-of-clinical-trials", "type": "clause", "offset": [129, 155]}, {"key": "in-the-territory", "type": "clause", "offset": [251, 267]}, {"key": "additional-clinical-trials", "type": "definition", "offset": [301, 327]}, {"key": "additional-indications", "type": "definition", "offset": [332, 354]}, {"key": "subject-to-the-approval", "type": "definition", "offset": [363, 386]}, {"key": "supervision-of-the", "type": "clause", "offset": [391, 409]}, {"key": "ongoing-development", "type": "clause", "offset": [429, 448]}], "samples": [{"hash": "9K5MZX2csxf", "uri": "/contracts/9K5MZX2csxf#line-extensions", "label": "Preliminary Research, Development and Marketing Agreement (Tularik Inc)", "score": 18.0, "published": true}, {"hash": "8zmTU8pQQk9", "uri": "/contracts/8zmTU8pQQk9#line-extensions", "label": "Preliminary Research, Development and Marketing Agreement (Tularik Inc)", "score": 18.0, "published": true}, {"hash": "7sDBhb0M8Jz", "uri": "/contracts/7sDBhb0M8Jz#line-extensions", "label": "Preliminary Research, Development and Marketing Agreement (Tularik Inc)", "score": 18.0, "published": true}], "hash": "3c047435055509fd823ee444bf18525c", "id": 1}, {"snippet": "JT and Tularik may each prepare and submit to the JDC for consideration plans for development of Product line extensions and the conduct of clinical trials covering indications other than those for which Products are being developed or commercialized in the Territory. Any such line extensions or any additional clinical trials for additional indications will be subject to the approval and supervision of the JDC as part of the ongoing Development of such Product. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.", "size": 4, "snippet_links": [{"key": "submit-to", "type": "definition", "offset": [36, 45]}, {"key": "the-jdc", "type": "clause", "offset": [46, 53]}, {"key": "product-line-extensions", "type": "clause", "offset": [97, 120]}, {"key": "conduct-of-clinical-trials", "type": "clause", "offset": [129, 155]}, {"key": "in-the-territory", "type": "clause", "offset": [251, 267]}, {"key": "additional-clinical-trials", "type": "definition", "offset": [301, 327]}, {"key": "additional-indications", "type": "definition", "offset": [332, 354]}, {"key": "subject-to-the-approval", "type": "definition", "offset": [363, 386]}, {"key": "supervision-of-the", "type": "clause", "offset": [391, 409]}, {"key": "ongoing-development", "type": "clause", "offset": [429, 448]}, {"key": "certain-confidential-information", "type": "clause", "offset": [474, 506]}, {"key": "contained-in", "type": "definition", "offset": [507, 519]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [564, 636]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [637, 653]}, {"key": "securities-act-of-1933", "type": "definition", "offset": [665, 687]}, {"key": "as-amended", "type": "definition", "offset": [689, 699]}], "samples": [{"hash": "k6RYECjgo2C", "uri": "/contracts/k6RYECjgo2C#line-extensions", "label": "Preliminary Research, Development and Marketing Agreement (Tularik Inc)", "score": 18.0, "published": true}, {"hash": "edcoroFZCoz", "uri": "/contracts/edcoroFZCoz#line-extensions", "label": "Preliminary Research, Development and Marketing Agreement (Tularik Inc)", "score": 18.0, "published": true}, {"hash": "dzmateT4xcM", "uri": "/contracts/dzmateT4xcM#line-extensions", "label": "Preliminary Research, Development and Marketing Agreement (Tularik Inc)", "score": 18.0, "published": true}], "hash": "dee16598538c7a6418c7af78af5c01f7", "id": 2}, {"snippet": "(a) In areas of the franchise territory not included in the initial service areas, the Grantee shall be required to extend its system pursuant to the following requirements:\n(1) No customer shall be refused service arbitrarily. Grantee is hereby authorized to extend the Cable System as necessary within the Village. To expedite the process of extending the Cable System into a new sub-division, the Village will forward to the Grantee an approved engineering plan of each project. Subject to the density requirements, the Grantee shall commence the design and construction process upon receipt of the final engineering plan. Upon notification from the Village that the first home in the project has been approved for building permit, the Grantee shall have a maximum of three (3) months to complete the construction/activation process within the project phase.\n(2) The Grantee must extend and make cable television service available to every dwelling unit in all unserved, developing areas having at least twenty (20) dwelling units planned per street mile, as measured from the existing system, and shall extend its system simultaneously with the installation of utility lines.\n(3) The Grantee must extend and make cable television service available to any isolated resident outside the initial service area requesting connection at the standard connection charge, if the connection to the isolated resident would require no more than a standard one hundred seventy- live (175) foot drop line.", "size": 4, "snippet_links": [{"key": "franchise-territory", "type": "definition", "offset": [20, 39]}, {"key": "not-included", "type": "clause", "offset": [40, 52]}, {"key": "service-areas", "type": "definition", "offset": [68, 81]}, {"key": "to-extend", "type": "clause", "offset": [113, 122]}, {"key": "pursuant-to-the", "type": "definition", "offset": [134, 149]}, {"key": "customer-shall", "type": "clause", "offset": [181, 195]}, {"key": "the-cable-system", "type": "clause", "offset": [267, 283]}, {"key": "the-village", "type": "clause", "offset": [304, 315]}, {"key": "the-process", "type": "clause", "offset": [329, 340]}, {"key": "new-sub", "type": "definition", "offset": [378, 385]}, {"key": "to-the-grantee", "type": "definition", "offset": [421, 435]}, {"key": "plan-of", "type": "definition", "offset": [460, 467]}, {"key": "subject-to-the", "type": "definition", "offset": [482, 496]}, {"key": "construction-process", "type": "clause", "offset": [561, 581]}, {"key": "upon-receipt-of", "type": "definition", "offset": [582, 597]}, {"key": "final-engineering", "type": "definition", "offset": [602, 619]}, {"key": "upon-notification", "type": "clause", "offset": [626, 643]}, {"key": "first-home", "type": "definition", "offset": [670, 680]}, {"key": "the-project", "type": "clause", "offset": [684, 695]}, {"key": "building-permit", "type": "clause", "offset": [718, 733]}, {"key": "the-construction", "type": "clause", "offset": [800, 816]}, {"key": "activation-process", "type": "clause", "offset": [817, 835]}, {"key": "project-phase", "type": "definition", "offset": [847, 860]}, {"key": "grantee-must", "type": "clause", "offset": [870, 882]}, {"key": "cable-television-service", "type": "clause", "offset": [899, 923]}, {"key": "available-to", "type": "definition", "offset": [924, 936]}, {"key": "dwelling-units", "type": "definition", "offset": [1019, 1033]}, {"key": "existing-system", "type": "definition", "offset": [1080, 1095]}, {"key": "installation-of", "type": "clause", "offset": [1149, 1164]}, {"key": "utility-lines", "type": "clause", "offset": [1165, 1178]}, {"key": "initial-service-area", "type": "clause", "offset": [1289, 1309]}, {"key": "standard-connection-charge", "type": "definition", "offset": [1339, 1365]}, {"key": "the-connection", "type": "clause", "offset": [1370, 1384]}, {"key": "foot-drop", "type": "clause", "offset": [1480, 1489]}], "samples": [{"hash": "ifBHObPFZg0", "uri": "/contracts/ifBHObPFZg0#line-extensions", "label": "Cable Television Franchise Agreement", "score": 26.5277614594, "published": true}, {"hash": "80e33QkEclV", "uri": "/contracts/80e33QkEclV#line-extensions", "label": "Cable Television Franchise Agreement", "score": 24.4528369904, "published": true}], "hash": "80d4a59a2b5896fb47077868b227688a", "id": 3}, {"snippet": "24.1 Client will provide Cardinal Health Account Management notification not less than thirty (30) days prior to receipt of a new product and forty-five (45) days prior to receipt of an acquired product.\n24.2 Client will provide the following information twenty (20) days prior to receipt of a new product and thirty-five (35) days prior to receipt of an acquired product:\na) Complete RFI\nb) Item Set Up\nc) Trade Letter\nd) MSDS\ne) Packing schematics (if applicable)\nf) Storage / shipping forecast\n24.3 Cardinal Health will use commercially reasonable efforts to launch new product within seventy-two (72) hours of initial receipt unless count discrepancies, missing paperwork, damage investigation, and other receiving anomalies interfere with efficient receiving and documentation.", "size": 3, "snippet_links": [{"key": "will-provide", "type": "clause", "offset": [12, 24]}, {"key": "management-notification", "type": "definition", "offset": [49, 72]}, {"key": "prior-to", "type": "clause", "offset": [104, 112]}, {"key": "receipt-of-a", "type": "clause", "offset": [113, 125]}, {"key": "new-product", "type": "clause", "offset": [126, 137]}, {"key": "acquired-product", "type": "definition", "offset": [186, 202]}, {"key": "provide-the", "type": "clause", "offset": [221, 232]}, {"key": "if-applicable", "type": "clause", "offset": [451, 464]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [523, 558]}, {"key": "hours-of", "type": "clause", "offset": [605, 613]}, {"key": "initial-receipt", "type": "clause", "offset": [614, 629]}, {"key": "and-documentation", "type": "clause", "offset": [764, 781]}], "samples": [{"hash": "g6Kuddv19U2", "uri": "/contracts/g6Kuddv19U2#line-extensions", "label": "Exclusive Distribution Agreement", "score": 28.901058197, "published": true}, {"hash": "gENQNGTtcyC", "uri": "/contracts/gENQNGTtcyC#line-extensions", "label": "Exclusive Distribution Agreement (Cumberland Pharmaceuticals Inc)", "score": 19.6214923859, "published": true}, {"hash": "9IEv4GckkOw", "uri": "/contracts/9IEv4GckkOw#line-extensions", "label": "Exclusive Distribution Agreement (Cumberland Pharmaceuticals Inc)", "score": 19.6132793427, "published": true}], "hash": "0f0e895eeb145fe7b2cf9de8f6d16ec0", "id": 4}, {"snippet": "In the event that the density requirements set forth in (a) are not satisfied, Comcast shall extend its Cable System to serve a Subscriber or Subscribers if such Subscriber or Subscribers are willing to share the cost of the extension, according to the following formula: The percentage by which the actual number of homes per mile on the extension falls short of the fifteen (15) homes per mile requirement specified in (a) above is the percentage of the construction costs that must be borne by the Subscriber(s).\ni. The term \u201cconstruction costs\u201d means the actual costs of the extension design, walkout, make-ready by other utilities, construction labor costs, and material costs. Construction costs do not include the cost of the drop, up to three hundred (300) feet, to the residence.\nii. By way of example, to reach a requesting Subscriber requires an extension of two (2) miles. There are six (6) homes within that two-mile distance. Given that the proposed extension contains 20% of the total number of homes specified in Section 3.1(a) for required service (15 homes per mile or 30 homes over two (2) miles), the Subscriber, with any other Subscribers who wish to contribute, must pay the remaining 80% of the construction costs. If two (2) persons agree to pay this additional cost, they would pay 80% of the construction cost or 40% each.\niii. If Comcast proposes to require a person or persons requesting extension to make a contribution in aid of extension, it must provide a detailed cost quotation to all potentially affected persons.", "size": 3, "snippet_links": [{"key": "in-the-event", "type": "clause", "offset": [0, 12]}, {"key": "cable-system", "type": "definition", "offset": [104, 116]}, {"key": "to-serve", "type": "definition", "offset": [117, 125]}, {"key": "cost-of", "type": "clause", "offset": [213, 220]}, {"key": "according-to", "type": "definition", "offset": [236, 248]}, {"key": "the-percentage", "type": "definition", "offset": [272, 286]}, {"key": "actual-number", "type": "definition", "offset": [300, 313]}, {"key": "per-mile", "type": "clause", "offset": [323, 331]}, {"key": "construction-costs", "type": "clause", "offset": [456, 474]}, {"key": "the-subscriber", "type": "definition", "offset": [497, 511]}, {"key": "the-term", "type": "definition", "offset": [519, 527]}, {"key": "costs-of", "type": "clause", "offset": [566, 574]}, {"key": "other-utilities", "type": "definition", "offset": [620, 635]}, {"key": "construction-labor-costs", "type": "clause", "offset": [637, 661]}, {"key": "material-costs", "type": "definition", "offset": [667, 681]}, {"key": "the-residence", "type": "clause", "offset": [774, 787]}, {"key": "extension-of", "type": "clause", "offset": [857, 869]}, {"key": "given-that", "type": "definition", "offset": [940, 950]}, {"key": "the-proposed", "type": "clause", "offset": [951, 963]}, {"key": "total-number-of", "type": "definition", "offset": [994, 1009]}, {"key": "required-service", "type": "clause", "offset": [1048, 1064]}, {"key": "other-subscribers", "type": "definition", "offset": [1142, 1159]}, {"key": "to-pay", "type": "clause", "offset": [1263, 1269]}, {"key": "additional-cost", "type": "definition", "offset": [1275, 1290]}, {"key": "person-or-persons", "type": "clause", "offset": [1387, 1404]}, {"key": "contribution-in-aid", "type": "clause", "offset": [1436, 1455]}, {"key": "provide-a", "type": "definition", "offset": [1478, 1487]}, {"key": "affected-persons", "type": "definition", "offset": [1531, 1547]}], "samples": [{"hash": "dSavpYkh3Jx", "uri": "/contracts/dSavpYkh3Jx#line-extensions", "label": "Cable Franchise Agreement", "score": 27.9265603925, "published": true}, {"hash": "ZaEnKgRRsK", "uri": "/contracts/ZaEnKgRRsK#line-extensions", "label": "Cable Television Franchise Agreement", "score": 27.8854942322, "published": true}], "hash": "cb56f143d961ae1cf48092c5e6b46eee", "id": 5}, {"snippet": "NeoGenesis and Tularik may each prepare and submit to the Steering Committee for consideration plans for Development of Shared Product line extensions and the conduct of clinical trials covering indications other than those for which Shared Products are then being Developed or Commercialized in the Territory. Any such line extensions or any additional clinical trials for additional indications will be subject to the approval and supervision of the Steering Committee as part of the ongoing Development of such Shared Product.", "size": 2, "snippet_links": [{"key": "submit-to", "type": "definition", "offset": [44, 53]}, {"key": "the-steering-committee", "type": "definition", "offset": [54, 76]}, {"key": "development-of", "type": "clause", "offset": [105, 119]}, {"key": "product-line-extensions", "type": "clause", "offset": [127, 150]}, {"key": "conduct-of-clinical-trials", "type": "clause", "offset": [159, 185]}, {"key": "shared-products", "type": "definition", "offset": [234, 249]}, {"key": "in-the-territory", "type": "clause", "offset": [293, 309]}, {"key": "additional-clinical-trials", "type": "definition", "offset": [343, 369]}, {"key": "additional-indications", "type": "definition", "offset": [374, 396]}, {"key": "subject-to-the-approval", "type": "definition", "offset": [405, 428]}, {"key": "supervision-of-the", "type": "clause", "offset": [433, 451]}, {"key": "ongoing-development", "type": "clause", "offset": [486, 505]}], "samples": [{"hash": "hVGbqeaI9pM", "uri": "/contracts/hVGbqeaI9pM#line-extensions", "label": "Confidentiality Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "ENLHympdpv", "uri": "/contracts/ENLHympdpv#line-extensions", "label": "Service Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "4ed8595734912a9c4bcbdc3d0c6ff044", "id": 6}, {"snippet": "NeoGenesis and Immusol may each prepare and submit to the Steering Committee for consideration plans for Development of Shared Product line extensions and the conduct of clinical trials covering indications other than those for which Shared Products are then being Developed or Commercialized in the Territory. Any such line extensions or any additional clinical trials for additional indications will be subject to the approval and supervision of the Steering Committee as part of the ongoing Development of such Shared Product.", "size": 2, "snippet_links": [{"key": "submit-to", "type": "definition", "offset": [44, 53]}, {"key": "the-steering-committee", "type": "definition", "offset": [54, 76]}, {"key": "development-of", "type": "clause", "offset": [105, 119]}, {"key": "product-line-extensions", "type": "clause", "offset": [127, 150]}, {"key": "conduct-of-clinical-trials", "type": "clause", "offset": [159, 185]}, {"key": "shared-products", "type": "definition", "offset": [234, 249]}, {"key": "in-the-territory", "type": "clause", "offset": [293, 309]}, {"key": "additional-clinical-trials", "type": "definition", "offset": [343, 369]}, {"key": "additional-indications", "type": "definition", "offset": [374, 396]}, {"key": "subject-to-the-approval", "type": "definition", "offset": [405, 428]}, {"key": "supervision-of-the", "type": "clause", "offset": [433, 451]}, {"key": "ongoing-development", "type": "clause", "offset": [486, 505]}], "samples": [{"hash": "kmC35jQC900", "uri": "/contracts/kmC35jQC900#line-extensions", "label": "Collaboration Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "gnetLaa3Ly6", "uri": "/contracts/gnetLaa3Ly6#line-extensions", "label": "Confidential Treatment Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "03e94216a4c874f4e8fff878185673ec", "id": 7}, {"snippet": "The Grantee shall extend its Cable System in the Franchise Area in accordance with \u00a7 A275-14 of Chapter A275.", "size": 2, "snippet_links": [{"key": "the-grantee", "type": "clause", "offset": [0, 11]}, {"key": "cable-system", "type": "definition", "offset": [29, 41]}, {"key": "franchise-area", "type": "definition", "offset": [49, 63]}, {"key": "in-accordance-with", "type": "clause", "offset": [64, 82]}], "samples": [{"hash": "hLkFNowdGjR", "uri": "/contracts/hLkFNowdGjR#line-extensions", "label": "Cable Service Franchise Agreement", "score": 20.5126628876, "published": true}, {"hash": "6RLJxM8VKPN", "uri": "/contracts/6RLJxM8VKPN#line-extensions", "label": "Cable Service Franchise Agreement", "score": 20.5126628876, "published": true}], "hash": "fe6a52f82372bbd6ffc206fb5616a0cc", "id": 8}, {"snippet": "In the event that Alpharma desires to develop Line Extensions to the Product which Alpharma deems beneficial to the Commercialization of the Product in the Territory, Alpharma shall deliver to the JEC a written proposal summarizing the proposed Line Extension together with a plan summarizing the activities necessary to develop the Line Extension through Regulatory Approval in the Territory similar to the approach outlined in the Development Plan. Upon receipt of such documentation, the JEC shall meet to discuss and consider such proposed Line Extension and approve any plans and budgets for any Durect Development Responsibilities. The Line Extension shall be encompassed in the definition of \u201cProduct\u201d under the Agreement, and subject to all the terms and conditions applicable thereto under this Agreement.", "size": 2, "snippet_links": [{"key": "in-the-event", "type": "clause", "offset": [0, 12]}, {"key": "to-develop", "type": "definition", "offset": [35, 45]}, {"key": "commercialization-of-the-product", "type": "clause", "offset": [116, 148]}, {"key": "deliver-to", "type": "definition", "offset": [182, 192]}, {"key": "written-proposal", "type": "definition", "offset": [203, 219]}, {"key": "proposed-line", "type": "definition", "offset": [236, 249]}, {"key": "the-activities", "type": "clause", "offset": [293, 307]}, {"key": "the-line", "type": "definition", "offset": [329, 337]}, {"key": "regulatory-approval-in-the-territory", "type": "clause", "offset": [356, 392]}, {"key": "similar-to", "type": "definition", "offset": [393, 403]}, {"key": "the-approach", "type": "clause", "offset": [404, 416]}, {"key": "the-development-plan", "type": "clause", "offset": [429, 449]}, {"key": "upon-receipt-of", "type": "definition", "offset": [451, 466]}, {"key": "meet-to-discuss", "type": "clause", "offset": [501, 516]}, {"key": "plans-and-budgets", "type": "definition", "offset": [575, 592]}, {"key": "durect-development-responsibilities", "type": "clause", "offset": [601, 636]}, {"key": "the-definition-of", "type": "clause", "offset": [681, 698]}, {"key": "the-agreement", "type": "clause", "offset": [715, 728]}, {"key": "subject-to", "type": "clause", "offset": [734, 744]}, {"key": "conditions-applicable", "type": "clause", "offset": [763, 784]}, {"key": "this-agreement", "type": "clause", "offset": [799, 813]}], "samples": [{"hash": "azD1FxFoKZA", "uri": "/contracts/azD1FxFoKZA#line-extensions", "label": "Development and License Agreement (Alpharma Inc)", "score": 21.0, "published": true}, {"hash": "kEQfDKxbCQ1", "uri": "/contracts/kEQfDKxbCQ1#line-extensions", "label": "Development and License Agreement (Durect Corp)", "score": 20.0, "published": true}], "hash": "7b455337387e38be7b6c5c50c99b2ff4", "id": 9}, {"snippet": "(i) For the purposes of this Agreement, the Licensed Product for new indications funded by NOVARTIS without reimbursement from ENDO or any diclofenac topical dispersible product in formulations different from the Licensed Product or concentrations other than 1% to be Developed and Commercialized as an Rx Product, shall be deemed to be a \u201cLine Extension.\u201d NOVARTIS retains all rights to research, Develop, and, subject to receipt of applicable Approvals, Commercialize Line Extensions inside and outside the Territory, subject only to ENDO\u2019s rights set forth in this Section 10.", "size": 2, "snippet_links": [{"key": "for-the-purposes-of-this-agreement", "type": "clause", "offset": [4, 38]}, {"key": "licensed-product", "type": "definition", "offset": [44, 60]}, {"key": "new-indications", "type": "clause", "offset": [65, 80]}, {"key": "by-novartis", "type": "clause", "offset": [88, 99]}, {"key": "rx-product", "type": "definition", "offset": [303, 313]}, {"key": "all-rights", "type": "clause", "offset": [374, 384]}, {"key": "subject-to", "type": "clause", "offset": [412, 422]}, {"key": "receipt-of", "type": "clause", "offset": [423, 433]}, {"key": "applicable-approvals", "type": "clause", "offset": [434, 454]}, {"key": "outside-the-territory", "type": "clause", "offset": [497, 518]}, {"key": "subject-only", "type": "definition", "offset": [520, 532]}, {"key": "section-10", "type": "clause", "offset": [568, 578]}], "samples": [{"hash": "gAeahD9FBcX", "uri": "/contracts/gAeahD9FBcX#line-extensions", "label": "License and Supply Agreement (Endo International PLC)", "score": 26.8535251617, "published": true}, {"hash": "8R6WCxKwwBg", "uri": "/contracts/8R6WCxKwwBg#line-extensions", "label": "License and Supply Agreement (Endo Pharmaceuticals Holdings Inc)", "score": 21.0, "published": true}], "hash": "4b4834c8e374bf5cded523ec2845f386", "id": 10}], "next_curs": "ClgSUmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjQLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhhsaW5lLWV4dGVuc2lvbnMjMDAwMDAwMGEMogECZW4YACAA", "clause": {"title": "Line Extensions", "children": [["early-extension", "Early extension"], ["", ""], ["line-extension-policy", "Line Extension Policy"], ["new-development-undergrounding", "New Development Undergrounding"], ["where-pge-extends", "Where PG&E extends"]], "parents": [["development-program", "Development Program"], ["area-to-be-served", "Area to Be Served"], ["general-requirements", "General Requirements"], ["cable-system-construction-and-technical-standards", "Cable System Construction and Technical Standards"], ["system-construction-operation-and-maintenance", "System Construction Operation and Maintenance"]], "size": 41, "id": "line-extensions", "related": [["time-extensions", "Time Extensions", "Time Extensions"], ["time-extension", "Time Extension", "Time Extension"], ["lease-extension", "Lease Extension", "Lease Extension"], ["term-extension", "Term Extension", "Term Extension"], ["territorial-extension", "Territorial Extension", "Territorial Extension"]], "related_snippets": [], "updated": "2025-07-24T06:49:05+00:00", "also_ask": [], "drafting_tip": null, "explanation": "The Line Extensions clause defines the terms under which additional infrastructure or service lines may be extended beyond the existing network or service area. Typically, this clause outlines the conditions, costs, and responsibilities for extending lines to new locations, such as new buildings or developments, and may specify who bears the financial burden\u2014whether it is the service provider, the customer, or shared between both. Its core practical function is to establish clear procedures and cost allocations for expanding service coverage, thereby preventing disputes and ensuring both parties understand their obligations when new connections are needed."}, "json": true, "cursor": ""}}